atopic dermatitis
Conditions
Interventions
Experimental group:Subcutaneous injection of mite allergen injection
Control group:None
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Outpatients aged 6-60 years old, regardless of gender 2) The clinical diagnosis is in line with AD (Hanifin and Rajka diagnostic criteria) 3) Allergen screening for house dust mites and/or dust mites allergy (generally recommended = grade 2), and allergic symptoms are repeatedly aggravated after exposure to dust mites 4) AD patients require stable disease (mild to moderate, BSA <10%, SCORAD <50 points, EASI <21 points) 5) The subjects themselves and their guardians voluntarily participated in the trial, signed the informed consent form, and agreed to conduct timely visits according to the investigator's requirements during the trial.
Exclusion criteria
Exclusion criteria: 1) Patients with poorly controlled and moderate to severe persistent asthma (FEV1<70%) 2) With severe pathology or immunodeficiency 3) Combined with malignant tumor line 4) Apply beta-blockers, even in patients with topical application 5) Patients with obvious cardiovascular system diseases 6) The compliance is poor, and the patient is difficult to adhere to the treatment for a long time due to various reasons 7) Special groups, such as pregnant women, or those with severe mental disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SCORAD;The invesitigator‘s global assessment;Eczema area and severity index;Dermatology Quality of Life Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| visual analogue scale, VAS;Asthma quality of life questionnaire,AQLQ;Rhinoconjunctivitis Quality of Life Quantitative Scale; | — |
Countries
China
Contacts
Public ContactYunsheng Liang
Dermatology Hospital of Southern Medical University
Outcome results
None listed